Vol 43, Issue 9

FDA clears Simtriyo, first NDSRI stimulant for ADHD ages 6 and older, as millions return to school—see what this means for treatment.

Experts dissect 10 common antidepressant myths, separating evidence from fear on efficacy, addiction, suicide risk, withdrawal, and safe tapering.